The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Good news about the break up of the Yooya deal. Now we get to keep a decent chunk of it again. Why have FFWD tweeted about Intensity's good results when our stake is to become only a fraction of what it was?? Just as well I have my Portage shares!
https://lemminginvestors.blogspot.com/2019/07/integumen-trading-update.html
Haven't posted much recently as I've been busy but have read everyone's posts this week and as a long term shareholder I just thought I add a few comments.
It's interesting the way in which FFWD is gradually becoming a fund of funds concentrating more and more on the life science and biotech sector. This is good news in many respects. (1) It gives greater clarity of the NPV of FFWD, as our investments are increasingly becoming listed companies, (2) it gives greater liquidity to sell as and when the board see fit, and (3) it gives greater diversification for reduced risk. We will soon have as listed investees: Vogogo, Regent Pacific, and Portage, and when they list next year also Juvenescence and Emmac. We know that Juvenescence and Emmac will significantly enhance the NPV, but also FFWD's exchange of Intensity shares for Portage is strategically a smart move as our holding in Portage will immediately increase the NPV upon listing on the Nasdaq.
Our other investees which are still privately owned are also those which should be the most value enhancing. A Leap Gaming sale and Factom series B should massively rerate FFWD also.
Great times ahead!
Great news about Emmac once again. Emmac really establishing itself now across Europe.
Have announced clinical collaboration with Merck
Have announced clinical collaboration with Merck
Have announced clinical collaboration with Merck
You must be understandably concerned. The tribulations of scrabble can lead to somewhat irrational behaviour on occasion.
Don't you ever sleep Snoots? You're not allergic to garlic and mirrors are you?
Yes it's a difficult one knowing what's best. I would be inclined to hold on for now and wait and see if Portage list on a more liquid market, in which case you may not need to transfer, unless you're in a real hurry to sell.
I was curious to know how I could sell my Portage shares if I needed to but I'm inclined now to wait and see how it pans out. Must admit I haven't read about the consolidation idea but I certainly wouldn't do anything to risk losing any shares.
Cheers Bod. Will probably hang on for a bit then.
They don't seem to RNS investee company news these days unless it has some bearing the FFWD cash position. But even if they did RNS the Emmac news I doubt whether it would impact on the share price positively. There's a persistent bear out there with a serious weed (not the Emmac kind) up his posterior unloading for some reason.
I still believe in the fundamentals though. Emmac alone when it IPOs could add NAV equivalent to our current market cap. We're ridiculously undervalued right now but also at a serious inflexion point if you compare NAV to market cap.
Does anyone know of any uk brokers which do CREST dealing of Portage shares? Cheers!
Emmac building nicely.
Just realised it's the same as the RNS a while back. Don't know why Contract Pharma are so slow in reporting it!
Interesting interview with Jay Smith. I like the fact that he said that Factom hopes to have series B closed in the near future, although he didn't specify why the delay. He also said that Factom is extremely well known within the blockchain industry, and Factom does not really have any blockchain competitors, as Factom has a data-centric business model, whereas most of the others are coin-centric.